YD Bio Ltd

YD Bio Limited operates in the biotechnology sector, focusing on methylation analysis technology. The company was originally incorporated in Delaware as True Velocity, Inc. on February 6, 2024, and later re-domesticated as a Cayman Islands exempted company limited by shares on November 14, 2024, changing its name to YD Bio Limited on November 18, 2024. This re-domestication was for the purpose of a Business Combination completed on August 28, 2025. YD Biopharma, incorporated in the Cayman Islands on March 14, 2024, acquired all equity interests of Yong Ding Biopharm Co., Ltd., a company incorporated in the Republic of China on April 23, 2013. On August 28, 2025, YD Bio Limited completed its Business Combination with Breeze and YD Biopharma, making both wholly-owned subsidiaries. Following this, a Patent Licensing and Technology Transfer Agreement between EG BioMed Co., LTD. and Yong Ding Biopharm Co., Ltd became effective on August 28, 2025. This agreement grants YD Bio Limited an exclusive sublicense to patents and know-how related to methylation analysis technology for breast cancer detection and applications. The agreement has a 20-year term and automatically renews for an additional 5 years unless both parties agree not to renew. The company announced an expanded U.S. presence with planned facilities on December 16, 2025. Its principal executive office is located in Taipei City 115001, Taiwan.